Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Saitama Medical University, Department of Rheumatology and Applied Immunology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible patients were diagnosed with RA, as defined by the ACR 1987 criteria or ACR/EULAR 2010 criteria. Patients had previous secondary inadequate response or were intolerant to a TNF antagonist other than certolizumab pegol.
Exclusion criteria
Exclusion criteria: Patients were excluded if they had history of demyelinating or convulsive disease of the central nervous system (e.g., multiple sclerosis and epilepsy), New York Heart Association Class III or IV congestive heart failure, infectious disease, hepatitis B or hepatitis C, malignant tumor or lymphoproliferative disorder, including lymphoma or signs and symptoms suggestive of lymphoproliferative disease. Patients with any indication of current or past tuberculosis as shown by clinical history, chest X-ray and/or positive tuberculin reaction test were also excluded unless preventive therapy by isoniazid was first taken.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease activity (DAS28, SDAI, CDAI), disability (HAQ-DI), Joint destruction (modified total Sharp score), adverse effects at week 0, 12, 24, 52. | — |
Countries
Japan
Contacts
Public ContactFumie Iino
Saitama Medical University Hospital Clinical trial
Outcome results
None listed